Core Viewpoint - Rani Therapeutics is actively engaging with investors through participation in two upcoming conferences in September 2024, showcasing its innovative oral delivery technology for biologics and drugs [1][2]. Group 1: Upcoming Conferences - Rani Therapeutics will participate in the H.C. Wainwright 26th Annual Global Investment Conference on September 10, 2024, at 4:30 pm E.T. at the Lotte New York Palace Hotel, with CEO Talat Imran presenting [1]. - The company will also be featured at the 2024 Cantor Global Healthcare Conference on September 18, 2024, at 11:30 am E.T. at the InterContinental Barclay Hotel, again with CEO Talat Imran presenting [1]. - Both conferences will include formats such as company presentations, fireside chats, and one-on-one investor meetings, allowing for direct engagement with potential investors [1]. Group 2: Company Overview - Rani Therapeutics is a clinical-stage biotherapeutics company focused on the development of orally administered biologics and drugs, aiming to replace traditional subcutaneous injections and intravenous infusions [2]. - The company has developed the RaniPill® capsule, a proprietary and patented platform technology that has undergone several preclinical and clinical studies to assess its safety, tolerability, and bioavailability [2].

SAN JOSE, Calif., July 29, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that the Company will participate in two upcoming investor conferences in August 2024. These conferences include: BTIG Virtual Biotechnology Conference Location: Virtual Date: Monday, August 5th – Tuesday, August 6th, 2024 Format: 1x1 Investor Meetings Canaccord 44th A ...

Company Overview - Rani Therapeutics is a clinical-stage biotherapeutics company focused on advancing technologies for the oral delivery of biologics and drugs [2] - The company has developed the RaniPill® capsule, a proprietary and patented platform technology designed to replace subcutaneous injection or intravenous infusion with oral dosing [2] - Rani Therapeutics has successfully conducted several preclinical and clinical studies to evaluate the safety, tolerability, and bioavailability of the RaniPill® capsule technology [2] Upcoming Events - Rani Therapeutics will participate in the BTIG Virtual Biotechnology Conference on August 5th-6th, 2024, featuring 1x1 investor meetings [1] - The company will also present at the Canaccord 44th Annual Growth Conference on August 13th, 2024, at 3:30 PM E.T., with a format including a company presentation and 1x1 investor meetings [3]

SAN JOSE, Calif., July 22, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it has entered into a securities purchase agreement with a single institutional investor for the purchase and sale of 2,800,000 shares of Rani Therapeutics' Class A common stock (the "Common Stock") and pre-funded warrants to purchase 446,753 shares of Common Stoc ...

SAN JOSE, Calif., July 22, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it has entered into a securities purchase agreement with a single institutional investor for the purchase and sale of 2,800,000 shares of Rani Therapeutics' Class A common stock (the "Common Stock") and pre-funded warrants to purchase 446,753 shares of Common Stoc ...

~ Rani and ProGen to share responsibilities for the development and commercialization of RT-114, including a 50/50 cost and revenue share arrangement ~ ~ New RT-114 obesity program combines ProGen's FC Fusion protein conjugated GLP-1/GLP-2 dual agonist, PG-102, with the RaniPill® capsule designed to provide a differentiated oral delivery mechanism with bioavailability comparable to subcutaneous injection ~ ~ Rani to host conference call today at 8:00 a.m. ET/5:00 a.m. PT ~ "This partnership brings together ...

WASHINGTON, DC 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________________ to ________________ Commission File Number: 001-40672 RANI THERAPEUTICS HOLDINGS, INC. FORM 10-Q (Exact Name of Registrant as Specified in its Charter) | Delaware | 86-3114789 | | --- | --- | | (State or other jurisdiction of incorporation or organizatio ...

First Quarter 2024 and Subsequent Highlights: Exhibit 99.1 Rani Therapeutics Reports First Quarter 2024 Financial Results; Provides Corporate Update - Announced Positive Topline Results from Phase 1 Study of an Oral Anti-Interleukin 12/23 Antibody (RT-111) - - Initiation of Phase 2 clinical trial for RT-102 for the treatment of osteoporosis expected in 2024 – - RaniPill HC to be ready for potential Phase 1 clinical trials in the second half of 2024 - SAN JOSE, Calif., May 6, 2024 --Rani Therapeutics Holding ...

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Q4 2023 Earnings Conference Call March 20, 2024 4:30 PM ET Company Participants Kiki Patel - Gilmartin Group LLC Talat Imran - Chief Executive Officer Arvinder Dhalla - Vice President, Clinical Development Svai Sanford - Chief Financial Officer Conference Call Participants Olivia Brayer - Cantor Fitzgerald Edward Nash - Canaccord Genuity Julian Harrison - BTIG John Vandermosten - Zacks Operator Welcome to the Rani Therapeutics Fourth Quarter and Full Year 2023 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 OR FORM 10-K ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Mark One) For the transition period from ________________ to ________________ ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 Commission File Number: 001-40672 RANI THERAPEUTICS HOLDINGS, INC. (Exact Name of Registrant as Specified in its Charter) Delawa ...